Circulating miR-21 as a Potential Biomarker for the Diagnosis of Oral Cancer: A Systematic Review with Meta-Analysis

Head and neck squamous cell carcinoma (HNSCC) is one of the main neoformations of the head–neck region and is characterized by the presence of squamous carcinomatous cells of the multi-layered epithelium lining the oral cavity, larynx, and pharynx. The annual incidence of squamous cell carcinoma of the head and neck (HNSCC) comprises approximately 600,000 new cases globally. Currently, the 5-year survival from HNSCC is less than 50%. Surgical, radiotherapy, and chemotherapy treatments strongly compromise patient quality of life. MicroRNAs (miRNAs) are a family of small noncoding endogenous RNAs that function in regulating gene expression by regulating several biological processes, including carcinogenesis. The main upregulated microRNAs associated with oral carcinoma are miR-21, miR-455-5p, miR-155-5p, miR-372, miR-373, miR-29b, miR-1246, miR-196a, and miR-181, while the main downregulated miRNAs are miR-204, miR-101, miR-32, miR-20a, miR-16, miR-17, and miR-125b. miR-21 represents one of the first oncomirs studied. The present systematic review work was performed based on the preferred reporting items for systematic review and meta-analysis (PRISMA) protocol. A search was carried out in the PubMed and Scopus databases with the use of keywords. This search produced 628 records which, after the elimination of duplicates and the application of the inclusion and exclusion criteria, led to 7 included articles. The heterogeneity of the studies according to the odds ratio was high, with a Q value of 26.616 (p < 0.001), and the I2 was 77.457% for specificity. The heterogeneity was high, with a Q value of 25.243 (p < 0.001) and the I2 was 76.231% for sensitivity. The heterogeneity of data showed a Q value of 27.815 (p < 0.001) and the I2 was 78.429%. Therefore, the random-effects model was selected. The diagnostic odds ratio was 7.620 (95% CI 3.613–16.070). The results showed that the sensitivity was 0.771 (95% CI 0.680–0.842) (p < 0.001) while, for specificity, we found 0.663 (95% CI 0.538–0.770) (p < 0.001). The negative likelihood ratio (NLR) was 0.321 (95% CI 0.186–0.554), and the positive likelihood ratio (PLR) was 2.144 (95% CI 1.563–2.943). The summary ROC plot demonstrates that the diagnostic test presents good specificity and sensitivity, and the area under the curve (AUC), as calculated from the graph, was 0.79.

[1]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.

[2]  H. Ishinaga,et al.  A longitudinal study on circulating miR-21 as a therapeutic effect marker in head and neck squamous cell carcinoma. , 2019, Carcinogenesis.

[3]  M. Saqib,et al.  Circulating miR-21 as a prognostic and predictive biomarker in oral squamous cell carcinoma , 2019, Pakistan journal of medical sciences.

[4]  Yuehua Wu,et al.  miR-31-5p Is a Potential Circulating Biomarker and Therapeutic Target for Oral Cancer , 2019, Molecular therapy. Nucleic acids.

[5]  N. Cirillo,et al.  Predictive Prognostic Value of Tissue-Based MicroRNA Expression in Oral Squamous Cell Carcinoma: A Systematic Review and Meta-analysis , 2018, Journal of dental research.

[6]  S. A. Haider,et al.  Genetic etiology of oral cancer. , 2017, Oral oncology.

[7]  J. Hess,et al.  Epidemiology and Molecular Biology of Head and Neck Cancer , 2017, Oncology Research and Treatment.

[8]  Siyi Li,et al.  Circulating microRNA-21 as a biomarker for the detection of various carcinomas: an updated meta-analysis based on 36 studies , 2015, Tumor Biology.

[9]  Xiaobing Fu,et al.  The miRNA network: micro-regulator of cell signaling in cancer , 2014, Expert review of anticancer therapy.

[10]  N. Yanaihara,et al.  MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma , 2014, BMC Cancer.

[11]  Ling Gao,et al.  Circulating microRNA-21 (MIR-21) and phosphatase and tensin homolog (PTEN) are promising novel biomarkers for detection of oral squamous cell carcinoma , 2014, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[12]  Mark Loeb,et al.  Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments , 2014, BMC Medical Research Methodology.

[13]  Ying Peng,et al.  Diagnostic and prognostic value of plasma microRNA deregulation in nasopharyngeal carcinoma , 2013, Cancer biology & therapy.

[14]  Ming-Yu Yang,et al.  Circulating miRNA is a novel marker for head and neck squamous cell carcinoma , 2012, Tumor Biology.

[15]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[16]  Susan Mallett,et al.  QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies , 2011, Annals of Internal Medicine.

[17]  Michele Tarsilla Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[18]  S. Shukla,et al.  Exploring Chemical Modifications for siRNA Therapeutics: A Structural and Functional Outlook , 2010, ChemMedChem.

[19]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. , 2009, Journal of clinical epidemiology.

[20]  C. Croce,et al.  MicroRNAs in Cancer. , 2009, Annual review of medicine.

[21]  S. Warnakulasuriya Global epidemiology of oral and oropharyngeal cancer. , 2009, Oral oncology.

[22]  Danish Sayed,et al.  MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. , 2008, Molecular biology of the cell.

[23]  Y. Hayashizaki,et al.  Cancer research with non‐coding RNA , 2006, Cancer science.

[24]  R. Shivdasani MicroRNAs: regulators of gene expression and cell differentiation. , 2006, Blood.

[25]  C. Croce MicroRNAs in leukemia. , 2006, Clinical advances in hematology & oncology : H&O.

[26]  A. Carvalho,et al.  Natural history of untreated head and neck cancer. , 2000, European journal of cancer.

[27]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[28]  A. Syrenicz,et al.  Expression of selected angiogenesis-related small microRNAs in patients with abnormally increased secretion of glucocorticoids. , 2019, Endokrynologia Polska.

[29]  N. Bahrami,et al.  Evaluation of Circulating Serum 3 Types of microRNA as Biomarkers of Oral Squamous Cell Carcinoma; a Pilot Study. , 2019, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[30]  S. Bala,et al.  Emerging role of non-coding RNA in oral cancer. , 2018, Cellular signalling.

[31]  D. Wiesenfeld,et al.  Oral Cancer. , 2018, Australian dental journal.

[32]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[33]  C. Croce,et al.  MicroRNAs in cancer. , 2014, Annual review of pathology.

[34]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.